Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
Merck KGaA shares have risen solidly over the past year, yet the longer term picture is still marked by a weak five year return, which puts a spotlight on whether the current price lines up with what the business earns. With fresh product news and portfolio reshaping now in play, the stock invites a closer look at how much of those earnings investors are being asked to pay for today. The share price has declined 27.4% over 5 years, so the current valuation question is how that track record...
The company said it now expects full-year net sales to range between $23.84 billion and $24.29 billion, against its prior forecast of between $23.29 billion and $24.18 billion.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.